Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Paclitaxel, Carboplatin, Epirubicin, Cyclophosphamide in TNBC
NCT04224922Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- May 2015
- Primary completion
- Jul 2016
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of carboplatin in triple-negative breast cancer (TNBC), sponsored by AstraZeneca. Started May 2015; status: completed.
02
Drugs
carboplatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04224922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04224922.